England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

The Trump Administration reversed course on plans to terminate the lease of a major Food and Drug Administration quality lab ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...